30,006 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Acquired by Birchview Capital LP

Key Points

• Birchview Capital LP has acquired a new stake in Kiniksa Pharmaceuticals International, purchasing 30,006 shares valued at approximately $666,000, which constitutes around 0.6% of its investment portfolio.
• Wall Street analysts maintain a positive outlook on Kiniksa Pharmaceuticals, with a consensus rating of "Buy" and an average target price of $41.17, including upgraded price targets from Jefferies and Wells Fargo.
• Recent insider trading activity shows that Kiniksa's CFO sold 18,889 shares for $621,259, reflecting a significant decrease in their ownership, alongside another insider selling 29,325 shares for $954,528.

Birchview Capital LP acquired a new position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The firm acquired 30,006 shares of the company's stock, valued at approximately $666,000. Kiniksa Pharmaceuticals International accounts for 0.6% of Birchview Capital LP's investment portfolio, making the stock its 29th biggest holding.

Other large investors have also modified their holdings of the company. GAMMA Investing LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after buying an additional 568 shares in the last quarter. US Bancorp DE acquired a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at about $33,000. Asset Management One Co. Ltd. acquired a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at about $41,000. Wealthquest Corp acquired a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at about $42,000. Finally, Lazard Asset Management LLC acquired a new stake in Kiniksa Pharmaceuticals International during the 4th quarter valued at approximately $61,000. Institutional investors and hedge funds own 53.95% of the company's stock.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, Director Thomas Malley sold 78,233 shares of the business's stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $33.09, for a total value of $2,588,729.97. Following the completion of the sale, the director owned 12,546 shares of the company's stock, valued at $415,147.14. The trade was a 86.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Eben Tessari sold 138,614 shares of the business's stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $33.20, for a total value of $4,601,984.80. Following the completion of the sale, the chief operating officer directly owned 49,915 shares of the company's stock, valued at $1,657,178. This represents a 73.52% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 558,403 shares of company stock valued at $18,078,671 in the last ninety days. Company insiders own 53.48% of the company's stock.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA traded up $0.20 during midday trading on Friday, reaching $35.71. The stock had a trading volume of 328,234 shares, compared to its average volume of 429,216. Kiniksa Pharmaceuticals International, plc has a 52 week low of $17.82 and a 52 week high of $35.84. The firm's 50 day moving average price is $30.95 and its 200-day moving average price is $26.49. The company has a market capitalization of $2.65 billion, a P/E ratio of 892.97 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. The business had revenue of $156.80 million for the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on KNSA. Wells Fargo & Company raised their price objective on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, July 9th. Jefferies Financial Group increased their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 30th. Finally, Wedbush reaffirmed an "outperform" rating and set a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $41.17.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.